Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.

Pérez-Peña J, Győrffy B, Amir E, Pandiella A, Ocaña A.

Breast Cancer Res Treat. 2018 Sep 11. doi: 10.1007/s10549-018-4965-x. [Epub ahead of print]

PMID:
30206781
2.

Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.

Guerra B, Martín-Rodríguez P, Díaz-Chico JC, McNaughton-Smith G, Jiménez-Alonso S, Hueso-Falcón I, Montero JC, Blanco R, León J, Rodríguez-González G, Estévez-Braun A, Pandiella A, Díaz-Chico BN, Fernández-Pérez L.

Oncotarget. 2018 Aug 14;9(63):32272. doi: 10.18632/oncotarget.26008. eCollection 2018 Aug 14.

3.

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results.

Ocaña A, Amir E, Pandiella A.

Oncotarget. 2018 Aug 7;9(61):31915-31919. doi: 10.18632/oncotarget.25739. eCollection 2018 Aug 7. Review.

4.

Colorectal cancer and medicinal plants: Principle findings from recent studies.

Benarba B, Pandiella A.

Biomed Pharmacother. 2018 Aug 9;107:408-423. doi: 10.1016/j.biopha.2018.08.006. [Epub ahead of print] Review.

PMID:
30099345
5.

The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation.

Centa A, Rodríguez-Barrueco R, Montero JC, Pandiella A.

Mol Oncol. 2018 Jun;12(7):1061-1076. doi: 10.1002/1878-0261.12310. Epub 2018 May 14.

6.

Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer.

Díaz-Rodríguez E, Sanz E, Pandiella A.

Int J Oncol. 2018 Jul;53(1):113-123. doi: 10.3892/ijo.2018.4373. Epub 2018 Apr 16.

7.

Resistance to Antibody-Drug Conjugates.

García-Alonso S, Ocaña A, Pandiella A.

Cancer Res. 2018 May 1;78(9):2159-2165. doi: 10.1158/0008-5472.CAN-17-3671. Epub 2018 Apr 13. Review.

PMID:
29653942
8.

Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.

Martínez-Canales S, López de Rodas M, Nuncia-Cantarero M, Páez R, Amir E, Győrffy B, Pandiella A, Galán-Moya EM, Ocaña A.

Cancer Med. 2018 May;7(5):1896-1907. doi: 10.1002/cam4.1406. Epub 2018 Mar 25.

9.

Transcriptome evolution from breast epithelial cells to basal-like tumors.

Santpere G, Alcaráz-Sanabria A, Corrales-Sánchez V, Pandiella A, Győrffy B, Ocaña A.

Oncotarget. 2017 Dec 8;9(1):453-463. doi: 10.18632/oncotarget.23065. eCollection 2018 Jan 2.

10.

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.

Perez-Peña J, Corrales-Sánchez V, Amir E, Pandiella A, Ocana A.

Sci Rep. 2017 Dec 13;7(1):17530. doi: 10.1038/s41598-017-17836-7.

11.

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.

Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero Á, Trigo JM, Muñoz M, Pandiella A, Diego NG, Bezares S, Caballero R, Carrasco E, Urruticoechea A.

Oncotarget. 2017 Apr 14;8(42):73144-73153. doi: 10.18632/oncotarget.17113. eCollection 2017 Sep 22.

12.

BET inhibitors as novel therapeutic agents in breast cancer.

Ocaña A, Nieto-Jiménez C, Pandiella A.

Oncotarget. 2017 Aug 1;8(41):71285-71291. doi: 10.18632/oncotarget.19744. eCollection 2017 Sep 19. Review.

13.

Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.

Orive-Ramos A, Seoane S, Ocaña A, Pandiella A, Montero JC.

Mol Oncol. 2017 Dec;11(12):1788-1805. doi: 10.1002/1878-0261.12145. Epub 2017 Oct 31.

14.

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.

Alcaraz-Sanabria A, Nieto-Jiménez C, Corrales-Sánchez V, Serrano-Oviedo L, Andrés-Pretel F, Montero JC, Burgos M, Llopis J, Galán-Moya EM, Pandiella A, Ocaña A.

Mol Cancer Ther. 2017 Nov;16(11):2552-2562. doi: 10.1158/1535-7163.MCT-17-0223. Epub 2017 Aug 28.

PMID:
28847989
15.

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.

Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J.

Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18.

PMID:
28821558
16.

Neutrophils in cancer: prognostic role and therapeutic strategies.

Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ.

Mol Cancer. 2017 Aug 15;16(1):137. doi: 10.1186/s12943-017-0707-7. Review.

17.

Antitumoral effect of Ocoxin in hepatocellular carcinoma.

Díaz-Rodríguez E, El-Mallah AM, Sanz E, Pandiella A.

Oncol Lett. 2017 Aug;14(2):1950-1958. doi: 10.3892/ol.2017.6440. Epub 2017 Jun 21.

18.

Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.

Ríos-Luci C, García-Alonso S, Díaz-Rodríguez E, Nadal-Serrano M, Arribas J, Ocaña A, Pandiella A.

Cancer Res. 2017 Sep 1;77(17):4639-4651. doi: 10.1158/0008-5472.CAN-16-3127. Epub 2017 Jul 7.

19.

Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors.

Martínez-Canales S, Cifuentes F, López De Rodas Gregorio M, Serrano-Oviedo L, Galán-Moya EM, Amir E, Pandiella A, Győrffy B, Ocaña A.

PLoS One. 2017 May 4;12(5):e0175128. doi: 10.1371/journal.pone.0175128. eCollection 2017.

20.

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Pérez-Peña J, Alcaraz-Sanabria A, Nieto-Jiménez C, Páez R, Corrales-Sánchez V, Serrano-Oviedo L, Wali VB, Patwardhan GA, Amir E, Győrffy B, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 28;8(13):21733-21740. doi: 10.18632/oncotarget.15562.

21.

Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs.

Tibau A, Díez-González L, Navarro B, Galán-Moya EM, Templeton AJ, Seruga B, Pandiella A, Amir E, Ocana A.

Mol Diagn Ther. 2017 Jun;21(3):337-343. doi: 10.1007/s40291-017-0267-y.

PMID:
28247182
22.

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.

Ocana A, Pandiella A.

Oncotarget. 2017 Mar 28;8(13):22218-22234. doi: 10.18632/oncotarget.14731. Review.

23.

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Nieto-Jiménez C, Alcaraz-Sanabria A, Pérez-Peña J, Corrales-Sánchez V, Serrano-Heras G, Galán-Moya EM, Serrano-Oviedo L, Montero JC, Burgos M, Llopis J, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 21;8(12):19478-19490. doi: 10.18632/oncotarget.14465.

24.

Multisite phosphorylation of P-Rex1 by protein kinase C.

Montero JC, Seoane S, García-Alonso S, Pandiella A.

Oncotarget. 2016 Nov 22;7(47):77937-77949. doi: 10.18632/oncotarget.12846.

25.

ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA.

Talamillo A, Grande L, Ruiz-Ontañon P, Velasquez C, Mollinedo P, Torices S, Sanchez-Gomez P, Aznar A, Esparis-Ogando A, Lopez-Lopez C, Lafita C, Berciano MT, Montero JA, Vazquez-Barquero A, Segura V, Villagra NT, Pandiella A, Lafarga M, Leon J, Martinez-Climent JA, Sanz-Moreno V, Fernandez-Luna JL.

Oncogene. 2017 Mar 23;36(12):1733-1744. doi: 10.1038/onc.2016.341. Epub 2016 Sep 19.

PMID:
27641332
26.

CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.

Guerra B, Martín-Rodríguez P, Díaz-Chico JC, McNaughton-Smith G, Jiménez-Alonso S, Hueso-Falcón I, Montero JC, Blanco R, León J, Rodríguez-González G, Estévez-Braun A, Pandiella A, Díaz-Chico BN, Fernández-Pérez L.

Oncotarget. 2017 May 2;8(18):29679-29698. doi: 10.18632/oncotarget.11425. Erratum in: Oncotarget. 2018 Aug 14;9(63):32272.

27.

Antiproliferative Effect of Synadenium grantii Hook f. stems (Euphorbiaceae) and a Rare Phorbol Diterpene Ester.

Campos A, Vendramini-Costa DB, Longato GB, Zermiani T, Ruiz AL, de Carvalho JE, Pandiella A, Cechinel Filho V.

Int J Toxicol. 2016 Nov;35(6):666-671. Epub 2016 Jul 27.

PMID:
27466346
28.

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.

Nieto-Jiménez C, Alcaraz-Sanabria A, Páez R, Pérez-Peña J, Corrales-Sánchez V, Pandiella A, Ocaña A.

Oncotarget. 2016 Jul 28;8(38):62834-62841. doi: 10.18632/oncotarget.10886. eCollection 2017 Sep 8.

29.

Targeting the EGF/HER Ligand-Receptor System in Cancer.

Esparís-Ogando A, Montero JC, Arribas J, Ocaña A, Pandiella A.

Curr Pharm Des. 2016;22(39):5887-5898. Review.

PMID:
27426127
30.

In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.

Pérez-Peña J, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Pandiella A, Ocaña A.

Mol Cancer Ther. 2016 Aug;15(8):1823-33. doi: 10.1158/1535-7163.MCT-16-0004. Epub 2016 Jun 2.

31.

Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.

Templeton AJ, Gonzalez LD, Vera-Badillo FE, Tibau A, Goldstein R, Šeruga B, Srikanthan A, Pandiella A, Amir E, Ocana A.

PLoS One. 2016 May 5;11(5):e0154789. doi: 10.1371/journal.pone.0154789. eCollection 2016. Review.

32.

Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.

Ocaña A, Díez-González L, Esparís-Ogando A, Montero JC, Amir E, Pandiella A.

Oncotarget. 2016 Jul 19;7(29):45042-45051. doi: 10.18632/oncotarget.8648.

33.

In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases.

Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A, Sánchez-Corrales V, Nieto-Jiménez C, Templeton AJ, Seruga B, Pandiella A, Amir E.

Oncotarget. 2016 Apr 19;7(16):22865-72. doi: 10.18632/oncotarget.8118.

34.

Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer.

Ocaña A, Pérez-Peña J, Díez-González L, Sánchez-Corrales V, Templeton A, Seruga B, Amir E, Pandiella A.

Breast Cancer Res Treat. 2016 Feb;156(1):1-8. doi: 10.1007/s10549-016-3720-4. Epub 2016 Feb 20.

PMID:
26897635
35.

Antitumoral effect of Ocoxin on acute myeloid leukemia.

Díaz-Rodríguez E, Hernández-García S, Sanz E, Pandiella A.

Oncotarget. 2016 Feb 2;7(5):6231-42. doi: 10.18632/oncotarget.6862.

36.

Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development.

Ocana A, Pandiella A.

Curr Cancer Drug Targets. 2017;17(1):48-52. Review.

PMID:
26648484
37.

Circulating DNA and Survival in Solid Tumors.

Ocaña A, Díez-González L, García-Olmo DC, Templeton AJ, Vera-Badillo F, José Escribano M, Serrano-Heras G, Corrales-Sánchez V, Seruga B, Andrés-Pretel F, Pandiella A, Amir E.

Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):399-406. doi: 10.1158/1055-9965.EPI-15-0893. Epub 2015 Nov 24. Review.

38.

Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses.

Ocana A, Ethier JL, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E.

Oncotarget. 2015 Nov 24;6(37):39538-49. doi: 10.18632/oncotarget.5946. Review.

39.

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.

Pandiella A, Morís F, Ocaña A, Núñez LE, Montero JC.

Oncotarget. 2015 Oct 20;6(32):32856-67. doi: 10.18632/oncotarget.5942.

40.

Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors.

Serrano-Heras G, Cuenca-López MD, Montero JC, Corrales-Sanchez V, Morales JC, Núñez LE, Morís F, Pandiella A, Ocaña A.

Oncotarget. 2015 Oct 13;6(31):31272-83. doi: 10.18632/oncotarget.5211.

41.

Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node.

Seoane S, Montero JC, Ocaña A, Pandiella A.

Oncogene. 2016 May;35(21):2756-65. doi: 10.1038/onc.2015.337. Epub 2015 Sep 14.

PMID:
26364598
42.

Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.

Montero JC, García-Alonso S, Ocaña A, Pandiella A.

Oncotarget. 2015 Oct 6;6(30):30057-71. doi: 10.18632/oncotarget.4996.

43.

Erratum: Achilles' heel of triple negative cancer.

Ocaña A, Montero JC, Pandiella A.

Oncoscience. 2014 Dec 13;2(7):659. eCollection 2015.

44.

Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer.

Cuenca-López MD, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Gomez-Juarez M, Gascón-Escribano MJ, Morales JC, Voisin V, Núñez LE, Morís F, Bader GD, Pandiella A, Ocaña A.

Oncotarget. 2015 Sep 29;6(29):27923-37. doi: 10.18632/oncotarget.4736.

45.

Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer.

Hernández-García S, González V, Sanz E, Pandiella A.

Nutr Cancer. 2015;67(7):1159-69. doi: 10.1080/01635581.2015.1068819. Epub 2015 Aug 4.

PMID:
26241555
46.

Modulation of cereblon levels by anti-myeloma agents.

Díaz-Rodríguez E, Pandiella A.

Leuk Lymphoma. 2016;57(1):167-76. doi: 10.3109/10428194.2015.1037752. Epub 2015 May 12.

PMID:
25860244
47.

Tumor-infiltrating lymphocytes in breast cancer: ready for prime time?

Ocaña A, Diez-Gónzález L, Adrover E, Fernández-Aramburo A, Pandiella A, Amir E.

J Clin Oncol. 2015 Apr 10;33(11):1298-9. doi: 10.1200/JCO.2014.59.7286. Epub 2015 Mar 9. No abstract available.

PMID:
25753437
48.

Achilles' heel of triple negative cancer.

Ocaña A, Montero JC, Pandiella A.

Oncoscience. 2014 Dec 13;1(12):763-4. eCollection 2014. No abstract available. Erratum in: Oncoscience. 2015;2(7):659.

49.

Achilles' heel of triple negative cancer.

Ocaña A, Montero JC, Pandiella A.

Oncoscience. 2014 Mar 15;1(2):115-6. eCollection 2014. No abstract available. Erratum in: Oncoscience. 2015;2(7):659.

50.

The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential.

Iglesias JM, Leis O, Pérez Ruiz E, Gumuzio Barrie J, Garcia-Garcia F, Aduriz A, Beloqui I, Hernandez-Garcia S, Lopez-Mato MP, Dopazo J, Pandiella A, Menendez JA, Martin AG.

Front Oncol. 2014 Nov 4;4:308. doi: 10.3389/fonc.2014.00308. eCollection 2014.

Supplemental Content

Loading ...
Support Center